molecules of the month


oral GyrB inhibitor

Ph. II for NTM-PD

phosphate prodrug of SPR719

bioRxiv, December 9, 2022

Spero Therapeutics, Cambridge, MA

SPR720 chemical structure oral GyrB inhibitor - Spero Therapeutics, Cambridge, MA
5 mins read

What is it? SPR720 (pVXc-486) is an oral prodrug of a dual inhibitor of the bacterial DNA gyrase and topoisomerase IV ATPase catalytic domains, GyrB and ParE. The molecule was in-licensed by Spero Therapeutics, a 2014 “Fierce 15” startup, from Vertex (WO2014014845A1, US20140031318), and is now Spero’s lead development program after Spero was issued a CRL for tebipenem and out-licensed tebipenem to GSK. Last year, the FDA lifted its clinical hold on SPR720, which was originally placed due to mortality findings in non-human primates (NHPs), despite demonstration of safety in a Ph. I trial (NCT03796910, 500-1,500 mg QD). The molecule now continues its Ph. II study in nontuberculous mycobacterial pulmonary disease (NTM-PD) due to Mycobacterium avium complex (MAC) (NCT05496374). Why…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: